Array BioPharma (NASDAQ: ARRY) announced today that it has appointed Andrew Robbins to the position of Senior Vice President of Commercial Operations. The creation of this new position reflects the Company’s continued transformation towards a commercial-stage company, as several products in the Array pipeline approach pivotal trials, including its wholly owned myelodysplastic syndrome and multiple myeloma programs. In his new role, Mr. Robbins will be responsible for working with Array’s research and development teams to refine the Company’s strategy, prioritizing portfolio investments and supporting corporate collaborations with Array’s strategic partners. As Array’s products move closer to market, he will develop launch plans and build an integrated sales and marketing team.
"I am delighted that Andy has decided to join the Array team,” said Ron Squarer, Chief Executive Officer. “I am confident his commercial development expertise and strategic insight will contribute to Array’s immediate and future successes."
Mr. Robbins has extensive commercial, development and strategic leadership expertise from a 15-year career in the pharmaceutical industry, with a specific focus on oncology/hematology products. Most recently he was at Hospira, Inc. where he served as General Manager/Vice President of the U.S. Alternate Site business unit, focused on the sales of pharmaceuticals and medical devices to outpatient oncology, surgery, pain and dialysis customers. In this role, he led a team of approximately 100 employees, including a national sales force, to deliver over $400 million in annual revenue. Prior to this, he was Vice President of Corporate Development and was responsible for global branded pharmaceutical marketing and business development, research and development portfolio prioritization, global strategy and corporate venture investing. During his tenure, he designed and executed a strategy to build a late-stage hematology/oncology and acute pain pipeline via licensing and acquisition. Mr. Robbins also served on the Board of Directors for three venture-backed healthcare companies, two of which were focused on innovative hematology/oncology products.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV